Sarcopenia in children with acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Musculoskeletal Health
• Cancer Treatment Complications

Background:

• Children with acute lymphoblastic leukemia (ALL) often face musculoskeletal issues during treatment.
• Understanding changes in skeletal muscle mass (SMM) is crucial for managing treatment-related morbidities.

Purpose of the Study:

• To analyze the changes in skeletal muscle mass (SMM) in children with ALL during therapy.
• To investigate the association between SMM changes and the burden of illness, measured by hospitalization duration.

Main Methods:

• Ninety-one children with ALL underwent dual-energy x-ray absorptiometry (DXA) scans at five time points during treatment.
• Appendicular lean mass was used to derive skeletal muscle mass (SMM).
• Inpatient days were recorded to quantify the burden of illness.

Main Results:

• SMM Z scores decreased significantly from -0.18 at diagnosis to -1.08 after six months of therapy.
• A partial recovery of SMM was observed between 12 to 24 months post-diagnosis.
• Serum creatinine levels, a surrogate for SMM, remained largely unchanged.
• The magnitude of SMM reduction during early treatment correlated with the duration of hospitalization (r=0.31, P<0.05).

Conclusions:

• Children with ALL experience substantial SMM reduction early in treatment, with incomplete recovery.
• The degree of SMM loss is linked to the overall burden of illness.
• These findings highlight SMM as a potential target for therapeutic interventions and a metric for efficacy assessment.